Gastric Cancer Clinical Trials (May 2026): 543 Recruiting Interventional Studies

Last updated: May 6, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Perioperative (Locally Advanced, Resectable)

Adding immunotherapy to perioperative chemo (FLOT or SOX) — a major active area in 2026:

• IO + perioperative chemo:
  • NCT07023315 — Cadonilimab + SOX as perioperative treatment (Phase 3)
  • NCT06949033 — Cadonilimab + perioperative SOX for diffuse/mixed gastric (Phase 3)
  • NCT06925243 — Neoadjuvant apatinib + sintilimab + perioperative SOX vs sintilimab+SOX (Phase 3)
  • NCT06028737 — Total neoadjuvant FLOT in locally advanced gastric/GEJ (Phase 2/3)
• Adjuvant after surgery:
  • NCT07366528 — Adjuvant oxaliplatin + S-1 vs docetaxel + S-1 for Stage III gastric (Phase 3)
  • NCT05482516 — Novel therapies in ctDNA-positive GI cancers (Phase 3)

Metastatic / Advanced — First-Line

First-line trials are organized by biomarker. The right trial depends on your HER2, CLDN18.2, MSI, and PD-L1 status:

• HER2-positive: (see the HER2+ gastric trials page for the full breakdown across lines of therapy)
  • NCT06731478 — Trastuzumab deruxtecan + chemo + pembrolizumab + trastuzumab in 1L HER2+ metastatic (Phase 3)
  • NCT06532006 — HLX22 + trastuzumab + chemo in HER2+ gastric (Phase 3)
  • NCT07315750 — Disitamab vedotin + trastuzumab + tislelizumab vs chemo + trastuzumab ± pembrolizumab in 1L HER2-high gastric/GEJ (Phase 3)
  • NCT06764875 — Rilvegostomig + fluoropyrimidine + trastuzumab deruxtecan (Phase 3)
  • NCT07118527 — SHR-A1811 + chemo + adebrelimab vs trastuzumab + chemo + pembrolizumab in untreated HER2+ gastric/GEJ (Phase 3)
• CLDN18.2-positive:
  • NCT06901531 — Zolbetuximab + pembrolizumab + chemo in CLDN18.2+ gastric/GEJ (Phase 3)
  • NCT07431281 — Sonesitatug vedotin + capecitabine ± rilvegostomig in 1L CLDN18.2+ HER2-negative gastric/GEJ/esophageal (Phase 3)
  • NCT07103668 — CLDN18.2-positive unresectable locally advanced gastric (Phase 3)
• MSI-H / dMMR:
  • NCT06346197 — Combination immune checkpoint inhibitors in MSI/dMMR esogastric adenocarcinoma (Phase 3)
• HER2− / Other 1L combinations:
  • NCT07221149 — Pumitamig (PD-L1 × VEGF bispecific) + chemo in esophageal/GEJ/gastric (Phase 3)
  • NCT06203600 — Adding nivolumab to standard treatment for advanced stomach/esophageal (Phase 3)
  • NCT06793917 — Tislelizumab + FOLFOX vs POF in locally advanced gastric (Phase 3)
  • NCT07392892 — PF-08634404 + chemo in 1L HER2-negative PD-L1-positive locally advanced/metastatic gastroesophageal (Phase 2/3)

Metastatic — Second-Line and Beyond

After first-line failure — ADCs and novel agents are the main active area:

• HER2-targeted ADCs (HER2+):
  • NCT07152405 — BL-M07D1 vs investigator's choice of chemo in HER2+ gastric/GEJ after failure of 1L anti-HER2 + chemo (Phase 3)
• CLDN18.2-targeted (CLDN18.2+):
  • NCT06346392 — AZD0901 (CLDN18.2 ADC) vs investigator's choice in 2L+ CLDN18.2+ advanced gastric (Phase 3)
  • NCT06238843 — IBI343 (CLDN18.2 ADC) monotherapy vs investigator's choice in previously treated CLDN18.2+ gastric (Phase 3)
  • NCT07284134 — JS107 vs investigator's choice in 2L+ CLDN18.2+ advanced gastric (Phase 3)
• Other novel agents:
  • NCT04342910 — Camrelizumab + apatinib after first-line platinum failure in PD-L1-positive gastric/GEJ (Phase 3)
  • NCT07270991 — Trifluridine/tipiracil + fruquintinib vs trifluridine/tipiracil alone in 3L+ metastatic gastroesophageal (Phase 3)

Peritoneal Disease

Trials specifically for peritoneal carcinomatosis — a common pattern of gastric cancer spread:

• • NCT05871099 — Laparoscopic gastrectomy + D2 lymphadenectomy + HIPEC (Phase 3)
  • NCT07304271 — Intraperitoneal paclitaxel + systemic therapy vs systemic alone (Phase 3)
  • NCT05303714 — PIPAC in multimodal therapy for oligometastatic peritoneal gastric (Phase 3)
  • NCT07001748 — Intra-abdominal paclitaxel + chemo (Phase 2/3)

Showing selected notable trials. View all 543 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions